Your browser doesn't support javascript.
loading
EXPLORING THE UNINTENDED CONSEQUENCES OF MISUSE OF WEGOVY AND OZEMPIC IN WEIGHT MANAGEMENT: A COMPREHENSIVE REVIEW
Int J Pharm Pharm Sci ; 2024 Jun; 16(6): 10-13
Article | IMSEAR | ID: sea-231186
In recent years, Glucagon-Like Peptide-1 (GLP-1) receptor agonists have emerged as promising options for weight management, offering not only glycemic control benefits but also significant reductions in body weight. Among these agents, Wegovy (semaglutide) and Ozempic (semaglutide) have gained attention for their efficacy in promoting weight loss, even in individuals without diabetes. However, the off-label use of these medications for weight management raises several questions and concerns regarding their safety, efficacy, and long-term effects. This comprehensive review aims to explore the complexities of GLP-1 agonists in weight management, focusing on their mechanism of action, clinical evidence, safety profile, dosing considerations, potential interactions, and future directions.
Key words
Full text: 1 Index: IMSEAR Journal: Int J Pharm Pharm Sci Year: 2024 Type: Article
Full text: 1 Index: IMSEAR Journal: Int J Pharm Pharm Sci Year: 2024 Type: Article